v3.19.3
Condensed Consolidated Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Revenue
Expenses:        
Research and development 4,751,000 3,591,000 11,582,000 14,549,000
General and administrative 2,276,000 2,020,000 7,391,000 8,233,000
Operating Expenses 7,027,000 5,611,000 18,973,000 22,782,000
Other income (expense):        
Interest income 187,000 80,000 407,000 198,000
Foreign exchange losses (4,000) (2,000) (23,000)
Total other income 183,000 80,000 405,000 175,000
Net loss (6,844,000) (5,531,000) (18,568,000) (22,607,000)
Unrealized gain/(loss) on securities available-for-sale (5,000) 9,000 13,000 3,000
Total comprehensive loss $ (6,849,000) $ (5,522,000) $ (18,555,000) $ (22,604,000)
Basic and diluted loss per common share (in dollars per share) $ (0.12) $ (0.16) $ (0.39) $ (0.71)
Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per common share (in thousands) (in shares) 55,454 34,587 47,315 32,039

Source